Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 24, No 16 (June 1), 2006: pp. 2570-2575
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.03.8349

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sharif, S.
Right arrow Articles by Evans, D. G. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sharif, S.
Right arrow Articles by Evans, D. G. R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Second Primary Tumors in Neurofibromatosis 1 Patients Treated for Optic Glioma: Substantial Risks After Radiotherapy

Saba Sharif, Rosalie Ferner, Jillian M. Birch, James E. Gillespie, H. Rao Gattamaneni, Michael E. Baser, D. Gareth R. Evans

From the Department of Clinical Genetics, St Mary's Hospital; Cancer Research UK Paediatric and Familial Cancer Research Group, Royal Manchester Children's Hospital; Department of Clinical Radiology, Manchester Royal Infirmary; Christie Hospital, Manchester; Department of Clinical Neurosciences, Guy's Kings and St Thomas' School of Medicine, Guy's Hospital, London, United Kingdom; and private practice, Los Angeles, CA

Address reprint requests to D. Gareth R. Evans, MD, FRCP, Department of Clinical Genetics, St Mary's Hospital (SM2), Hathersage Rd, Manchester M13 OJH, United Kingdom; e-mail: Gareth.evans{at}cmmc.nhs.uk

PURPOSE: Optic pathway gliomas (OPGs) are the most common CNS tumor in neurofibromatosis 1 (NF1) patients. We evaluated the long-term risk of second tumors in NF1-related OPGs after radiotherapy.

PATIENTS AND METHODS: We reviewed 80 NF1 OPG patients from two NF1 clinics to evaluate the long-term risk of developing subsequent nervous system tumors, with or without radiotherapy.

RESULTS: Fifty-eight patients were assessable for second tumors. Nine (50%) of 18 patients who received radiotherapy after their OPGs developed 12 second tumors in 308 person-years of follow-up after radiotherapy. Eight (20%) of 40 patients who were not treated with radiotherapy developed nine tumors in 721 person-years of follow-up after diagnosis of their OPGs. The relative risk of second nervous system tumor after radiotherapy was 3.04 (95% CI, 1.29 to 7.15).

CONCLUSION: There is a significantly increased risk of second nervous system tumors in those NF1 patients who received radiotherapy for their OPGs, especially when treated in childhood. Thus radiotherapy should only be used if absolutely essential in children with NF1.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J Child NeurolHome page
A. J. Sievert and M. J. Fisher
Pediatric Low-Grade Gliomas
J Child Neurol, November 1, 2009; 24(11): 1397 - 1408.
[Abstract] [PDF]


Home page
Clin. Cancer Res.Home page
X. Qi, Z. Chu, Y. Y. Mahller, K. F. Stringer, D. P. Witte, and T. P. Cripe
Cancer-Selective Targeting and Cytotoxicity by Liposomal-Coupled Lysosomal Saposin C Protein
Clin. Cancer Res., September 15, 2009; 15(18): 5840 - 5851.
[Abstract] [Full Text] [PDF]


Home page
Br J OphthalmolHome page
C F Parsa and S Givrad
Pilocytic astrocytomas as hamartomas: implications for treatment
Br J Ophthalmol, January 1, 2008; 92(1): 3 - 6.
[Full Text] [PDF]


Home page
J. Med. Genet.Home page
S Sharif, A Moran, S M Huson, R Iddenden, A Shenton, E Howard, and D G R Evans
Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening
J. Med. Genet., August 1, 2007; 44(8): 481 - 484.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Guerin, M. Hawkins, A. Shamsaldin, C. Guibout, I. Diallo, O. Oberlin, L. Brugieres, and F. de Vathaire
Treatment-Adjusted Predisposition to Second Malignant Neoplasms After a Solid Cancer in Childhood: A Case-Control Study
J. Clin. Oncol., July 1, 2007; 25(19): 2833 - 2839.
[Abstract] [Full Text] [PDF]


Home page
RadioGraphicsHome page
E. M. Chung, C. S. Specht, and J. W. Schroeder
From the Archives of the AFIP: Pediatric Orbit Tumors and Tumorlike Lesions: Neuroepithelial Lesions of the Ocular Globe and Optic Nerve
RadioGraphics, July 1, 2007; 27(4): 1159 - 1186.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
R. E Ferner, S. M Huson, N. Thomas, C. Moss, H. Willshaw, D G. Evans, M. Upadhyaya, R. Towers, M. Gleeson, C. Steiger, et al.
Guidelines for the diagnosis and management of individuals with neurofibromatosis 1
J. Med. Genet., February 1, 2007; 44(2): 81 - 88.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online